114 related articles for article (PubMed ID: 17150261)
1. Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy.
Konstantinopoulos PA; Papavassiliou AG
Trends Pharmacol Sci; 2007 Jan; 28(1):6-13. PubMed ID: 17150261
[TBL] [Abstract][Full Text] [Related]
2. Novel aspects of mevalonate pathway inhibitors as antitumor agents.
Thurnher M; Nussbaumer O; Gruenbacher G
Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099
[TBL] [Abstract][Full Text] [Related]
3. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Nat Rev Drug Discov; 2007 Jul; 6(7):541-55. PubMed ID: 17585331
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
5. High-content assay to study protein prenylation.
Simonen M; Ibig-Rehm Y; Hofmann G; Zimmermann J; Albrecht G; Magnier M; Heidinger V; Gabriel D
J Biomol Screen; 2008 Jul; 13(6):456-67. PubMed ID: 18509097
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
[TBL] [Abstract][Full Text] [Related]
8. Prenylation inhibitors: a novel class of antiviral agents.
Einav S; Glenn JS
J Antimicrob Chemother; 2003 Dec; 52(6):883-6. PubMed ID: 14613953
[TBL] [Abstract][Full Text] [Related]
9. Strategies for optimizing combinations of molecularly targeted anticancer agents.
Dancey JE; Chen HX
Nat Rev Drug Discov; 2006 Aug; 5(8):649-59. PubMed ID: 16883303
[TBL] [Abstract][Full Text] [Related]
10. High glucose induced endothelial cell growth inhibition is associated with an increase in TGFbeta1 secretion and inhibition of Ras prenylation via suppression of the mevalonate pathway.
Mather A; Chen XM; McGinn S; Field MJ; Sumual S; Mangiafico S; Zhang Y; Kelly DJ; Pollock CA
Int J Biochem Cell Biol; 2009 Mar; 41(3):561-9. PubMed ID: 18692592
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase inhibitors as anticancer agents.
Konstantinopoulos PA; Karamouzis MV; Papatsoris AG; Papavassiliou AG
Int J Biochem Cell Biol; 2008; 40(6-7):1156-68. PubMed ID: 18164645
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
Riester D; Hildmann C; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
[TBL] [Abstract][Full Text] [Related]
13. Rational combinations using HDAC inhibitors.
Bots M; Johnstone RW
Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
[TBL] [Abstract][Full Text] [Related]
14. RAS: target for cancer therapy.
Saxena N; Lahiri SS; Hambarde S; Tripathi RP
Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
16. Targeting the mevalonate pathway for improved anticancer therapy.
Fritz G
Curr Cancer Drug Targets; 2009 Aug; 9(5):626-38. PubMed ID: 19508172
[TBL] [Abstract][Full Text] [Related]
17. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
Rogers MJ
Calcif Tissue Int; 2004 Dec; 75(6):451-61. PubMed ID: 15332174
[TBL] [Abstract][Full Text] [Related]
18. Nonphosphate inhibitors of IspE protein, a kinase in the non-mevalonate pathway for isoprenoid biosynthesis and a potential target for antimalarial therapy.
Hirsch AK; Lauw S; Gersbach P; Schweizer WB; Rohdich F; Eisenreich W; Bacher A; Diederich F
ChemMedChem; 2007 Jun; 2(6):806-10. PubMed ID: 17361977
[No Abstract] [Full Text] [Related]
19. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
20. Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents.
Garattini E; Gianni' M; Terao M
Vitam Horm; 2007; 75():301-54. PubMed ID: 17368321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
